Occam has recruited Michael Bailey, President and CEO of AVEO Oncology, to the Board of Directors of IMV Inc. [IMV]. IMV is a clinical-stage biopharmaceutical company pioneering a new class of cancer-targeted immunotherapies and vaccines based on the company’s proprietary drug delivery platform. The company is currently assessing its lead candidate, DPX-Survivac, in advanced ovarian cancer as well as a combination therapy in multiple clinical studies with Merck.
To IMV’s Board, Bailey brings noteworthy, entrepreneurial commercial expertise and a successful track record in bringing cancer drugs to market. Bailey joined AVEO in 2010 as the company’s Chief Commercial Officer, took on the role of Chief Business Officer in 2013, and was appointed President, CEO, and a member of the Board of Directors in 2015. Prior to AVEO, Bailey served as SVP Business Development and Chief Commercial Officer of Synta Pharmaceuticals. He came to Synta from ImClone Systems where he led the worldwide commercial organization and held responsibility for the planning and launch of ERBITUX® (cetuximab) across multiple oncology indications.